70岁及以上患者甲状腺结节评估的获益与风险定量分析
该研究回顾性分析1995至2015年间1129例≥70岁、2527个≥1 cm甲状腺结节患者的超声与细针穿刺数据,发现仅1.5%为显著风险甲状腺癌且均可术前识别,中位随访4年期间非甲状腺恶性肿瘤或冠心病与死亡率升高相关(HR=2.32)。作者认为对无高风险表现的老年患者手术管理应有所节制。
要点
- ≥70岁患者中细针穿刺安全,67.3%细胞学为良性。
- 仅1.5%患者检出显著风险甲状腺癌,且均可术前通过影像和/或细胞学识别。
- 非甲状腺恶性肿瘤或冠心病与死亡率升高相关(HR=2.32,95%CI 1.66-3.26,P<0.01)。
核心结论
- 对于≥70岁患者,超声和细针穿刺是安全的,有助于识别显著风险甲状腺癌和良性细胞学。
- 对于无高风险表现的≥70岁患者,手术管理应有所节制,尤其在发现合并症时。
研究设计与样本
- 回顾性分析1995年至2015年间连续评估的≥70岁患者,均接受超声和细针穿刺检查。
- 共纳入1129例患者,2527个≥1 cm结节;收集临床、超声、组织学数据及合并症和结局。
- 显著风险甲状腺癌定义为未分化癌、髓样癌、低分化癌或存在远处转移。
主要发现
- 细针穿刺在所有患者中安全;67.3%的患者细胞学为良性。
- 细针穿刺导致208例患者接受手术,其中93例(44.7%)组织病理学为良性。
- 在所有接受细针穿刺的患者中,仅17例(1.5%)检出显著风险甲状腺癌,均术前可通过影像和/或细胞学识别。
- 这些显著风险甲状腺癌导致了所有甲状腺癌死亡(n=10;0.9%)。
- 其余1112例患者中,中位随访4年期间确认160例死亡(14.4%),均非甲状腺癌相关。
关键数值与推荐
- 显著风险甲状腺癌定义为未分化癌、髓样癌、低分化癌或存在远处转移。
- 非甲状腺恶性肿瘤或冠心病与死亡率升高相关(HR=2.32,95%CI 1.66-3.26,P<0.01)。
临床怎么用
- 对于≥70岁患者,超声和细针穿刺可用于识别显著风险甲状腺癌和良性细胞学。
- 作者认为,对于无高风险表现的≥70岁患者,手术管理应有所节制,尤其在发现合并症时。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In older patients, thyroid nodules are frequently detected and referred for evaluation, though usually prove to be benign disease or low-risk cancer. Therefore, management should be guided not solely by malignancy risk, but also by the relative risks of any intervention. Unfortunately, few such data are available for patients ≥70 years old. METHODS: All consecutive patients ≥70 years old assessed by ultrasound (US) and fine-needle aspiration (FNA) between 1995 and 2015 were analyzed. Clinical, US, and histologic data, including patient comorbidities and outcomes, were obtained. Imaging and cytology results from initial evaluation were reviewed to detect significant-risk thyroid cancer (SRTC), which was defined as anaplastic, medullary, or poorly differentiated carcinoma, or the presence of distant metastases. Overall survival analyses were then performed to assist with risk-to-benefit assessment. RESULTS: A total of 1129 patients ≥70 years old with 2527 nodules ≥1 cm were evaluated. FNA was safe in all, and cytology proved benign in 67.3% of patients. However, FNA led to surgery in 208 patients, of whom 93 (44.7%) had benign histopathology. Among all patients who underwent FNA, only 17 (1.5%) SRTC were identified, all of which were preoperatively identifiable by imaging and/or cytology. These SRTC were responsible for all (n = 10; 0.9%) thyroid cancer deaths. Among all other patients (n = 1112), 160 deaths (14.4%) were confirmed during a median follow-up of four years. None of these were thyroid cancer related. Survival analysis for these 1112 patients demonstrated that a separate non-thyroidal malignancy or coronary artery disease at the time of nodule evaluation was associated with increased mortality compared to those without these diagnoses (hazard ratio = 2.32 [confidence interval 1.66-3.26]; p < 0.01), confirming these are important variables to identify prior to thyroid nodule evaluation. CONCLUSIONS: For patients ≥70 years old, US and FNA are safe and prove helpful in identifying SRTC and benign cytology. However, the surgical management of patients ≥70 years old presenting without high-risk findings should be tempered, especially when comorbid illness is identified.
引用
- Wang Z, Vyas CM, Van Benschoten O, et al. Quantitative Analysis of the Benefits and Risk of Thyroid Nodule Evaluation in Patients ≥70 Years Old. Thyroid. 2018. PMID: 29608439. doi:10.1089/thy.2017.0655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。